» Articles » PMID: 32901432

Idiopathic Hypersomnia and Other Hypersomnia Syndromes

Overview
Specialty Neurology
Date 2020 Sep 9
PMID 32901432
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

There are numerous disorders of known or presumed neurologic origin that result in excessive daytime sleepiness, collectively known as the central disorders of hypersomnolence. These include narcolepsy types 1 and 2, idiopathic hypersomnia, Kleine-Levin syndrome, and hypersomnia due to or associated with medical disease, neurologic disease, psychiatric disease, medications or substances, and insufficient sleep durations. This chapter focuses on the treatment of nonnarcoleptic hypersomnia syndromes, from those that are commonly encountered in neurologic practice, such as hypersomnia due to Parkinson's disease, to those that are exceedingly rare but present with dramatic manifestations, such as Kleine-Levin syndrome. The level of evidence for the treatment of sleepiness in these disorders is generally lower than in the well-characterized syndrome of narcolepsy, but available clinical and randomized, controlled trial data can provide guidance for the management of each of these disorders. Treatments vary by diagnosis but may include modafinil/armodafinil, traditional psychostimulants, solriamfetol, pitolisant, clarithromycin, flumazenil, sodium oxybate, melatonin, methylprednisolone, and lithium.

Citing Articles

Diagnostic challenges and burden of idiopathic hypersomnia: a systematic literature review.

Boulanger T, Pigeon P, Crawford S Sleep Adv. 2024; 5(1):zpae059.

PMID: 39211350 PMC: 11359170. DOI: 10.1093/sleepadvances/zpae059.


A scoping review of the evidence on pharmacological and nonpharmacological interventions for idiopathic hypersomnia.

Saini V, Saini S J Clin Sleep Med. 2024; 20(10):1685-1704.

PMID: 38963076 PMC: 11446129. DOI: 10.5664/jcsm.11250.


Brain fog in central disorders of hypersomnolence: a review.

Rosenberg R, Thorpy M, Doghramji K, Morse A J Clin Sleep Med. 2024; 20(4):643-651.

PMID: 38217475 PMC: 10985301. DOI: 10.5664/jcsm.11014.


Recommended protocols for the Multiple Sleep Latency Test and Maintenance of Wakefulness Test in children: guidance from the American Academy of Sleep Medicine.

Maski K, Amos L, Carter J, Koch E, Kazmi U, Rosen C J Clin Sleep Med. 2023; 20(4):631-641.

PMID: 38149645 PMC: 10985297. DOI: 10.5664/jcsm.10974.


Antidotes in Clinical Toxicology-Critical Review.

Kobylarz D, Noga M, Frydrych A, Milan J, Morawiec A, Glaca A Toxics. 2023; 11(9).

PMID: 37755734 PMC: 10534475. DOI: 10.3390/toxics11090723.


References
1.
Huang Y, Lin Y, Guilleminault C . Polysomnography in Kleine-Levin syndrome. Neurology. 2008; 70(10):795-801. DOI: 10.1212/01.wnl.0000304133.00875.2b. View

2.
Trotti L, Saini P, Koola C, LaBarbera V, Bliwise D, Rye D . Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients. J Clin Sleep Med. 2016; 12(10):1389-1394. PMC: 5033741. DOI: 10.5664/jcsm.6196. View

3.
DeBattista C, Doghramji K, Menza M, Rosenthal M, Fieve R . Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003; 64(9):1057-64. DOI: 10.4088/jcp.v64n0911. View

4.
Anderson K, Pilsworth S, Sharples L, Smith I, Shneerson J . Idiopathic hypersomnia: a study of 77 cases. Sleep. 2007; 30(10):1274-81. PMC: 2266276. DOI: 10.1093/sleep/30.10.1274. View

5.
Mayer G, Benes H, Young P, Bitterlich M, Rodenbeck A . Modafinil in the treatment of idiopathic hypersomnia without long sleep time--a randomized, double-blind, placebo-controlled study. J Sleep Res. 2014; 24(1):74-81. DOI: 10.1111/jsr.12201. View